Drugs / Anti-Human CD70 T-Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07647744 | Jun 2026 → Jun 2029 expected | renal cell carcinoma | Hrain Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-Human CD70 T-Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647744 ↗ |
| Modality | Cell therapy | “Autologous genetically modified anti-Human CD70 CAR transduced T cells” NCT07647744 ↗ |
| Target | CD70 | “Autologous genetically modified anti-Human CD70 CAR transduced T cells” NCT07647744 ↗ |